FDA Launches AI-Driven Pilot for Real-Time Clinical Trials to Expedite Drug Approvals
The Food and Drug Administration (FDA) has announced a groundbreaking pilot program that utilizes artificial intelligence (AI) and cloud computing to monitor clinical trial data in real time. This initiative aims to significantly reduce the time required for the approval of new drugs, devices, and medications. The pilot involves pharmaceutical companies AstraZeneca and Amgen, who will implement the system in their respective clinical trials. The FDA's Chief Artificial Intelligence Officer, Jeremy Walsh, emphasized that the program could potentially cut clinical trial timelines by up to 40%, without compromising safety. The FDA is also seeking public and industry input on how AI technologies can enhance efficiency and decision-making in early-phase clinical trials, with responses due by May 29. 
